TABOOLA.COM LTD. (TBLA) Spending and interest coverage
- R&D / revenue · 12 months: Value 7.78%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.07%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 7.78% | Research and development expense / revenue. Period ending 2026-06-30. $152.62M ÷ $1.96B × 100 ≈ 7.78% |
| Stock-based compensation / revenue · 12 months | 3.07% | Share-based compensation / revenue. Period ending 2026-06-30. $60.17M ÷ $1.96B × 100 ≈ 3.07% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 152.62M USD | Research and Development Expense |
| Revenue | 1.96B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 60.17M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 126.92M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $152.62M | $1.96B | $60.17M | $126.92M | (m) | 7.78% | 3.07% | (m) | (m) |
| 2026-03-31 | $151.67M | $1.95B | $62.61M | $119.70M | (m) | 7.77% | 3.21% | (m) | (m) |
| 2025-12-31 | $148.04M | $1.91B | $63.94M | $44.06M | (m) | 7.74% | 3.34% | (m) | (m) |
| 2025-09-30 | $147.48M | $1.88B | $63.01M | $47.51M | (m) | 7.84% | 3.35% | (m) | (m) |
| 2025-06-30 | $146.34M | $1.82B | $64.48M | $45.56M | (m) | 8.05% | 3.55% | (m) | (m) |
| 2025-03-31 | $142.15M | $1.78B | $66.21M | $37.89M | (m) | 7.99% | 3.72% | (m) | (m) |
| 2024-12-31 | $142.44M | $1.77B | $67.10M | $25.92M | (m) | 8.06% | 3.80% | (m) | (m) |
| 2024-09-30 | $140.64M | $1.69B | $67.36M | $-12.51M | (m) | 8.30% | 3.97% | (m) | (m) |
| 2024-06-30 | $139.81M | $1.62B | $66.42M | $-35.80M | (m) | 8.62% | 4.09% | (m) | (m) |
| 2024-03-31 | $140.52M | $1.53B | $64.65M | $-53.17M | (m) | 9.21% | 4.24% | (m) | (m) |
| 2023-12-31 | $136.25M | $1.44B | $64.33M | $-63.74M | (m) | 9.46% | 4.47% | (m) | (m) |
| 2023-09-30 | $130.42M | $1.39B | $64.82M | $-47.50M | (m) | 9.38% | 4.66% | (m) | (m) |
| 2023-06-30 | $130.77M | $1.36B | $67.28M | $-50.21M | (m) | 9.59% | 4.93% | (m) | (m) |
| 2023-03-31 | $130.85M | $1.37B | $71.17M | $-34.76M | (m) | 9.52% | 5.18% | (m) | (m) |
| 2022-12-31 | $129.28M | $1.40B | $74.92M | $-13.66M | (m) | 9.23% | 5.35% | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $117.93M | $1.38B | $127.96M | $-13.27M | (m) | 8.56% | 9.28% | (m) | (m) |
| 2020-12-31 | $99.42M | $1.19B | $28.28M | $26.19M | (m) | 8.36% | 2.38% | (m) | (m) |
| 2019-12-31 | $84.71M | $1.09B | $8.25M | $-19.64M | (m) | 7.74% | 0.75% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rackspace Technology, Inc. (RXT) | United States | $1.073B | -10.35 |
| TripAdvisor, Inc. (TRIP) | United States | $1.000B | 321.35 |
| CEVA INC (CEVA) | United States | $0.971B | -121.14 |
| Sabre Corp (SABR) | United States | $0.916B | 1.18 |
| HEALTHSTREAM INC (HSTM) | United States | $0.845B | |
| Bumble Inc. (BMBL) | United States | $0.320B | 21.65 |
| System1, Inc. (SST) | United States | $0.287B | -1.64 |
| DoubleVerify Holdings, Inc. (DV) | United States | $2.072B | 28.53 |
| Health Catalyst, Inc. (HCAT) | United States | $0.132B | -0.56 |
| Eva Live Inc (GOAI) | United States | $0.083B |